6 assets in Reproductive System Cancer

Therapeutic assets addressing Reproductive System Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Reproductive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (55)
Dexasone Reproductive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (48)
Diphenhydramine Reproductive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (48)
Epinephrine Reproductive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (48)
Ibuprofen Reproductive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (48)
Prgn-2009 Reproductive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (48)